Carson Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Carson Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$207K	–	142
2022 Q3	$207K	Buy	+300	New	+$189K	0.23%	114
2022 Q2	–	Sell	-300	Closed	-$210K	–	133
2022 Q1	$210K	Buy	+300	New	+$190K	0.21%	124

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Carson Advisory's REGN Position: Q4 2022 in Review

Carson Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 300 shares — an estimated $207K sold.

Carson Advisory first reported a position in REGN in Q1 2022 and held it in 2 quarters. The position peaked at $210K in Q1 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Carson Advisory reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Carson Advisory sold 300 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $207K.
Carson Advisory first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Carson Advisory's Regeneron Pharmaceuticals position peaked at $210K in Q1 2022.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Carson Advisory's 13F filing for Q4 2022, filed 8 Feb 2023.